Antti Haring1, Teemu J Murtola1,2, Kirsi Talala3, Kimmo Taari4, Teuvo L J Tammela1,2, Anssi Auvinen5. 1. a School of Medicine , University of Tampere , Tampere , Finland. 2. b Department of Urology , Tampere University Hospital , Tampere , Finland. 3. c The Finnish Cancer Registry , Helsinki , Finland. 4. d Department of Urology , University of Helsinki and Helsinki University Hospital , Helsinki , Finland. 5. e School of Health Sciences , University of Tampere , Tampere , Finland.
Abstract
OBJECTIVE:Diabetic men have lowered overall prostate cancer (PCa) risk, while their risk of high-grade disease may be elevated. The antidiabetic drug metformin may reduce the risk. This study evaluated PCa incidence among users of metformin and other antidiabetic drugs in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). METHODS:The study population (78,615 men) was linked to the national prescription database. Hazard ratios (HRs) and 95% confidence intervals (CIs) for PCa were estimated using Cox regression, with medication use as a time-dependent variable. The effect of diabetes was estimated by comparing antidiabetic drug users to non-users, while drug-specific effects were evaluated within antidiabetic drug users. Analyses were performed in both study arms of FinRSPC. RESULTS: Compared to non-users, men using antidiabetic drugs had lowered overall PCa risk (HR 0.85, 95% CI 0.79-0.92), and this association was not affected by PCa screening. However, the risk of metastatic PCa was increased (HR 1.44, 95% CI 1.09-1.91). Among antidiabetic drug users, metformin decreased overall PCa risk (HR 0.81, 95% CI 0.69-0.95) in a dose-dependent manner. When stratified by FinRSPC study arm, the risk reduction was observed only in the screening arm. Sulphonylureas increased the risk of metastatic PCa (HR 2.04, 95% CI 1.11-3.77). Use of thiazoledenediones or insulin was not associated with PCa risk. CONCLUSION: Among antidiabetic drug users, metformin lowered the overall PCa risk, while the risk of metastatic disease was elevated in sulphonylurea users. As sulphonylureas stimulate insulin secretion, the results suggest that hyperinsulinemia may be a risk factor for PCa.
RCT Entities:
OBJECTIVE:Diabeticmen have lowered overall prostate cancer (PCa) risk, while their risk of high-grade disease may be elevated. The antidiabetic drugmetformin may reduce the risk. This study evaluated PCa incidence among users of metformin and other antidiabetic drugs in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). METHODS: The study population (78,615 men) was linked to the national prescription database. Hazard ratios (HRs) and 95% confidence intervals (CIs) for PCa were estimated using Cox regression, with medication use as a time-dependent variable. The effect of diabetes was estimated by comparing antidiabetic drug users to non-users, while drug-specific effects were evaluated within antidiabetic drug users. Analyses were performed in both study arms of FinRSPC. RESULTS: Compared to non-users, men using antidiabetic drugs had lowered overall PCa risk (HR 0.85, 95% CI 0.79-0.92), and this association was not affected by PCa screening. However, the risk of metastatic PCa was increased (HR 1.44, 95% CI 1.09-1.91). Among antidiabetic drug users, metformin decreased overall PCa risk (HR 0.81, 95% CI 0.69-0.95) in a dose-dependent manner. When stratified by FinRSPC study arm, the risk reduction was observed only in the screening arm. Sulphonylureas increased the risk of metastatic PCa (HR 2.04, 95% CI 1.11-3.77). Use of thiazoledenediones or insulin was not associated with PCa risk. CONCLUSION: Among antidiabetic drug users, metformin lowered the overall PCa risk, while the risk of metastatic disease was elevated in sulphonylurea users. As sulphonylureas stimulate insulin secretion, the results suggest that hyperinsulinemia may be a risk factor for PCa.
Authors: José Manuel Sánchez-Maldonado; Ricardo Collado; Antonio José Cabrera-Serrano; Rob Ter Horst; Fernando Gálvez-Montosa; Inmaculada Robles-Fernández; Verónica Arenas-Rodríguez; Blanca Cano-Gutiérrez; Olivier Bakker; María Inmaculada Bravo-Fernández; Francisco José García-Verdejo; José Antonio López López; Jesús Olivares-Ruiz; Miguel Ángel López-Nevot; Laura Fernández-Puerta; José Manuel Cózar-Olmo; Yang Li; Mihai G Netea; Manuel Jurado; Jose Antonio Lorente; Pedro Sánchez-Rovira; María Jesús Álvarez-Cubero; Juan Sainz Journal: Cancers (Basel) Date: 2022-05-12 Impact factor: 6.575
Authors: Danielle Crawley; Florence Chamberlain; Hans Garmo; Sarah Rudman; Björn Zethelius; Lars Holmberg; Jan Adolfsson; Par Stattin; Paul Carroll; Mieke Van Hemelrijck Journal: Ecancermedicalscience Date: 2018-01-25
Authors: E Lin; Hans Garmo; Mieke Van Hemelrijck; Jan Adolfsson; Pär Stattin; Björn Zethelius; Danielle Crawley Journal: BMC Cancer Date: 2020-06-15 Impact factor: 4.430